Tiburio Therapeutics

About:

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.

Website: https://www.tiburio.com/

Twitter/X: tiburiot/

Top Investors: New Enterprise Associates, Alexandria Venture Investments, Longitude Capital, Lundbeckfonden Ventures

Description:

Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.The company's compounds aid in the treatment of non-functioning pituitary adenoma using a dopamine-somatostatin chimeric molecule that has the potential to shrink or halt tumor growth, providing patients with effective treatment for rare neuroendocrine tumors and endocrine diseases.

Total Funding Amount:

$31M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2018-01-01

Contact Email:

nfo(AT)tiburio.com

Founders:

Chris Adams, Imran Babar, James McArthur, Michael Culler

Number of Employees:

1-10

Last Funding Date:

2019-01-03

IPO Status:

Private

Industries:

© 2025 bioDAO.ai